UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
American journal of transplantation, ISSN 1600-6135, 07/2020, Volume 20, Issue 7, pp. 1941 - 1943
colchicine | infectious disease | infection and infectious agents – viral | clinical research/practice | kidney transplantation/nephrology | immunosuppressive regimens | Transplantation | Life Sciences & Biomedicine | Surgery | Science & Technology | Pandemics | Humans | Middle Aged | Colchicine - administration & dosage | Male | Transplant Recipients | COVID-19 | SARS-CoV-2 | Darunavir - administration & dosage | Pneumonia, Viral - complications | Betacoronavirus | Coronavirus Infections - complications | Female | Mycophenolic Acid - administration & dosage | Immunosuppressive Agents - administration & dosage | Tacrolimus - administration & dosage | Kidney Failure, Chronic - surgery | Cytokines - metabolism | Ritonavir - administration & dosage | Tacrolimus - blood | Pneumonia, Viral - therapy | Cobicistat - administration & dosage | Treatment Outcome | Kidney Transplantation | Hydroxychloroquine - administration & dosage | Coronavirus Infections - therapy | Kidney Failure, Chronic - complications | Lopinavir - administration & dosage | Aged | Drug Combinations | Kidney transplantation
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 06/2020, Volume 18, Issue 6, pp. 1320 - 1323
plasma level | anticoagulant | COVID‐19 | antiviral agents | DOAC | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Betacoronavirus - pathogenicity | Dabigatran - adverse effects | Dabigatran - administration & dosage | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Male | Antithrombins - administration & dosage | Pyridones - blood | Thiazoles - adverse effects | Factor Xa Inhibitors - administration & dosage | COVID-19 | Pyridines - adverse effects | SARS-CoV-2 | Drug Interactions | Factor Xa Inhibitors - blood | Pyrazoles - blood | Patient Safety | Aged, 80 and over | Pyridines - administration & dosage | Risk Assessment | Administration, Oral | Risk Factors | Antiviral Agents - administration & dosage | Coronavirus Infections - virology | Antiviral Agents - adverse effects | Factor Xa Inhibitors - adverse effects | Antithrombins - blood | Pneumonia, Viral - diagnosis | Italy | Darunavir - adverse effects | Hemorrhage - chemically induced | Thiazoles - blood | Pandemics | Thiazoles - administration & dosage | Pyridones - administration & dosage | Ritonavir - adverse effects | Female | Pyrazoles - adverse effects | Severity of Illness Index | Coronavirus Infections - diagnosis | Betacoronavirus - drug effects | Dabigatran - blood | Pyrazoles - administration & dosage | Pyridines - blood | Antithrombins - adverse effects | Aged | Drug Monitoring | Pneumonia, Viral - virology | Lopinavir - adverse effects | Pyridones - adverse effects | Anticoagulants | Plasma | Antiviral agents | Ritonavir | Lopinavir | Plasma levels | Hospitalization | Patients | Thrombosis | Index Medicus
Journal Article
AIDS (London), ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Virology | Antiviral agents | General aspects | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Epidemiology. Vaccinations | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy | Index Medicus | AIDS/HIV | genital tract | sexual transmission | antiretroviral therapy | pharmacokinetics | prophylaxis | women
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2008, Volume 52, Issue 7, pp. 569 - 576
endothelial function | human immunodeficiency virus | cardiovascular disease risk | antiretroviral therapy | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Antiviral agents | Immunopathology | Viral diseases | Biological and medical sciences | Medical sciences | Immunodeficiencies | Cardiology. Vascular system | Infectious diseases | Pharmacology. Drug treatments | Viral diseases of the lymphoid tissue and the blood. Aids | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Antibiotics. Antiinfectious agents. Antiparasitic agents | HIV-1 | Lamivudine - administration & dosage | Prospective Studies | Humans | Endothelium, Vascular - drug effects | Male | Stavudine - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Time Factors | Adult | Brachial Artery - physiopathology | Female | Brachial Artery - drug effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Ritonavir - administration & dosage | Lopinavir | CD4 Lymphocyte Count | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Endothelium, Vascular - pathology | HIV Infections - drug therapy | Pyrimidinones - administration & dosage | HIV Infections - physiopathology | Studies | Ultrasonic imaging | Human immunodeficiency virus--HIV | Deflation | Aging | Clinical trials | Infections | Diabetes | Drug therapy | Risk factors | Cholesterol | Veins & arteries | Index Medicus | Abridged Index Medicus
Journal Article
AIDS (London), ISSN 0269-9370, 2013, Volume 27, Issue 5, pp. 803 - 813
Infectious Diseases | Immunology | Life Sciences & Biomedicine | Science & Technology | Virology | Antiviral agents | Immunopathology | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Antibiotics. Antiinfectious agents. Antiparasitic agents | HIV-1 | United States - epidemiology | Lamivudine - administration & dosage | Humans | HIV Seropositivity - mortality | HIV Seropositivity - drug therapy | Nevirapine - adverse effects | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Adenine - adverse effects | Time Factors | Deoxycytidine - adverse effects | HIV Infections - mortality | Dideoxynucleosides - adverse effects | Antiretroviral Therapy, Highly Active - methods | Dideoxynucleosides - administration & dosage | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Risk Factors | Organophosphonates - adverse effects | Europe - epidemiology | Benzoxazines - adverse effects | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Lopinavir - administration & dosage | HIV Infections - drug therapy | Nevirapine - administration & dosage | Deoxycytidine - analogs & derivatives | Drug Combinations | Lopinavir - adverse effects | Cohort Studies | Index Medicus | AIDS/HIV
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 381, Issue 9883, pp. 2091 - 2099
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiviral agents | General aspects | Infectious diseases | Pharmacology. Drug treatments | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Antibiotics. Antiinfectious agents. Antiparasitic agents | Nucleosides - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | HIV Infections - virology | Humans | Male | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | Nucleotides - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Lopinavir - administration & dosage | Adult | Female | HIV Infections - drug therapy | Drug Therapy, Combination | Raltegravir Potassium | Complications and side effects | Reverse transcriptase inhibitors | Dosage and administration | Drug therapy | HIV infection | Low income groups | Studies | Antiretroviral drugs | Plasma | Hepatitis | Consent | Human immunodeficiency virus--HIV | Homeostasis | Drug resistance | Viral infections | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
American journal of transplantation, ISSN 1600-6135, 07/2020, Volume 20, Issue 7, pp. 1849 - 1858
treatment | coronavirus | solid organ transplantation | COVID‐19 | SARS‐CoV‐2 | outcome | Transplantation | Life Sciences & Biomedicine | Surgery | Science & Technology | Pandemics | Humans | Middle Aged | Male | Organ Transplantation | Coronavirus Infections - mortality | Transplant Recipients | COVID-19 | SARS-CoV-2 | Pneumonia, Viral - complications | Betacoronavirus | Coronavirus Infections - complications | Female | Retrospective Studies | Immunosuppressive Agents - administration & dosage | Interferon-beta - administration & dosage | Ritonavir - administration & dosage | Pneumonia, Viral - therapy | Antiviral Agents - administration & dosage | Fever | Hydroxychloroquine - administration & dosage | Spain - epidemiology | Coronavirus Infections - therapy | Lopinavir - administration & dosage | Immunosuppressive Agents - adverse effects | Aged | Pneumonia, Viral - mortality | Radiography, Thoracic | Drug Combinations | Severe acute respiratory syndrome coronavirus 2 | Hydroxychloroquine | Transplants & implants | Ritonavir | Lopinavir | Interferon | Coronaviruses | Health risk assessment | Index Medicus
Journal Article
Pharmacotherapy, ISSN 0277-0008, 05/2020, Volume 40, Issue 5, pp. 416 - 437
dialysis | renal | antivirals | cytochrome P450 | infectious disease | liver | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Pandemics | Alanine - adverse effects | Adrenal Cortex Hormones | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Thiazoles - administration & dosage | Hydroxychloroquine - adverse effects | Thiazoles - adverse effects | Alanine - analogs & derivatives | Alanine - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Ritonavir - adverse effects | Ribavirin - administration & dosage | Betacoronavirus | Antibodies, Monoclonal, Humanized - adverse effects | Ritonavir - administration & dosage | Immunomodulation | Azetidines - adverse effects | Chloroquine - adverse effects | Antiviral Agents - administration & dosage | Adenosine Monophosphate - adverse effects | Hydroxychloroquine - administration & dosage | Nelfinavir - adverse effects | Interferon-alpha - administration & dosage | Azetidines - administration & dosage | Ribavirin - adverse effects | Adenosine Monophosphate - administration & dosage | Adenosine Monophosphate - analogs & derivatives | Antiviral Agents - adverse effects | Coronavirus Infections - therapy | Immunization, Passive | Lopinavir - administration & dosage | Sulfonamides - adverse effects | Chloroquine - administration & dosage | Interferon-alpha - adverse effects | Nelfinavir - administration & dosage | Drug Combinations | Lopinavir - adverse effects | Sulfonamides - administration & dosage | Severe acute respiratory syndrome coronavirus 2 | COVID-19 | Antiviral agents | Therapeutic applications | Clinical trials | Coronaviruses | Drug therapy | Patients | Index Medicus | Reviews of Therapeutics | Review of Therapeutics
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2006, Volume 368, Issue 9534, pp. 476 - 482
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Immunopathology | General aspects | Infectious diseases | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Dideoxynucleosides - administration & dosage | Organophosphates - administration & dosage | Lamivudine - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | Humans | Lopinavir | Pyrimidinones - therapeutic use | Organophosphates - therapeutic use | Carbamates - administration & dosage | HIV Protease Inhibitors - administration & dosage | HIV-1 - genetics | Reverse Transcriptase Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Sulfonamides - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | HIV Infections - drug therapy | Dideoxynucleosides - therapeutic use | Pyrimidinones - administration & dosage | Reverse Transcriptase Inhibitors - therapeutic use | Carbamates - therapeutic use | Drug Therapy, Combination | Sulfonamides - administration & dosage | Dosage and administration | Protease inhibitors | Comparative analysis | Drug therapy | HIV infection | Antiviral agents | Research | Drug therapy, Combination | Health aspects | Anti-HIV agents | Antiretroviral drugs | Human immunodeficiency virus--HIV | Samples | Clinical trials | Comparative studies | Clinical medicine | Disease control | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 11/2008, Volume 359, Issue 21, pp. 2233 - 2244
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | General aspects | Infectious diseases | Viral diseases | Viral diseases of the lymphoid tissue and the blood. Aids | Biological and medical sciences | Medical sciences | Human viral diseases | HIV-1 | Lamivudine - administration & dosage | Follow-Up Studies | Humans | Infant | Male | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Ritonavir - adverse effects | Treatment Failure | Female | HIV Infections - mortality | Drug Therapy, Combination | Drug Administration Schedule | Ritonavir - administration & dosage | Zidovudine - adverse effects | Anti-HIV Agents - adverse effects | Lopinavir | Pyrimidinones - adverse effects | CD4 Lymphocyte Count | Infectious Disease Transmission, Vertical | Disease Progression | HIV Infections - drug therapy | Pyrimidinones - administration & dosage | Antiviral agents | Control | Patient outcomes | Dosage and administration | HIV infection in children | Infants | Diagnosis | Antiretroviral drugs | Hospitals | Acquired immune deficiency syndrome--AIDS |